Efficacy of Anlotinib Plus Docetaxel in Advanced NSCLC Previously Treated with Platinum-Based Chemotherapy: A Systematic Review and Meta-Analysis
<b>Background/Objectives</b>: Anlotinib is a novel oral antiangiogenic tyrosine kinase inhibitor (TKI) approved as a third-line treatment for advanced non-small-cell lung cancer (NSCLC). However, its efficacy in combination with docetaxel remains incompletely understood. Given the need f...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-04-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/18/5/652 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849327091033571328 |
|---|---|
| author | Helal F. Hetta Saleh F. Alqifari Khaled Alshehri Amirah Alhowiti Saud S. Alharbi Hyder Mirghani Tariq Alrasheed Mohamed E. A. Mostafa Mohammed Sheikh Mahmoud Elodemi Sultan A. Alhumaid Yasmin N. Ramadan Noura H. Abd Ellah Reem Sayad |
| author_facet | Helal F. Hetta Saleh F. Alqifari Khaled Alshehri Amirah Alhowiti Saud S. Alharbi Hyder Mirghani Tariq Alrasheed Mohamed E. A. Mostafa Mohammed Sheikh Mahmoud Elodemi Sultan A. Alhumaid Yasmin N. Ramadan Noura H. Abd Ellah Reem Sayad |
| author_sort | Helal F. Hetta |
| collection | DOAJ |
| description | <b>Background/Objectives</b>: Anlotinib is a novel oral antiangiogenic tyrosine kinase inhibitor (TKI) approved as a third-line treatment for advanced non-small-cell lung cancer (NSCLC). However, its efficacy in combination with docetaxel remains incompletely understood. Given the need for effective second-line therapies after platinum-based chemotherapy, this systematic review aims to evaluate the therapeutic potential of anlotinib plus docetaxel in advanced NSCLC. <b>Methods</b>: The PubMed, WOS, Medline, and Scopus databases were screened for published articles up to 12 April 2024. We included RCTs comparing anlotinib plus docetaxel with docetaxel alone in advanced NSCLC after receiving platinum-based chemotherapy, reporting progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR) as outcomes for both groups. <b>Results</b>: Our systematic review included three randomized controlled trials (RCTs) with a total of 151 patients in the anlotinib plus docetaxel group and 132 in the docetaxel-only group. Meta-analysis results demonstrated that the combination therapy significantly prolonged PFS (mean difference (MD) = 2.98, 95% confidence interval (CI), 1.95–4.00; <i>p</i> < 0.00001) and improved ORR (risk ratio (RR) = 3.04, 95% CI = 1.77–5.24; <i>p</i> < 0.00001). Additionally, the DCR was notably higher in the combination group (RR = 1.58, 95% CI = 1.34–1.87; <i>p</i> < 0.00001). <b>Conclusions</b>: Anlotinib plus docetaxel appears to be more effective as a second-line treatment of advanced NSCLC than docetaxel in prolonging PFS and increasing ORR and DCR. |
| format | Article |
| id | doaj-art-72362811ba5b44b09e8fb69077ad29cd |
| institution | Kabale University |
| issn | 1424-8247 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj-art-72362811ba5b44b09e8fb69077ad29cd2025-08-20T03:47:58ZengMDPI AGPharmaceuticals1424-82472025-04-0118565210.3390/ph18050652Efficacy of Anlotinib Plus Docetaxel in Advanced NSCLC Previously Treated with Platinum-Based Chemotherapy: A Systematic Review and Meta-AnalysisHelal F. Hetta0Saleh F. Alqifari1Khaled Alshehri2Amirah Alhowiti3Saud S. Alharbi4Hyder Mirghani5Tariq Alrasheed6Mohamed E. A. Mostafa7Mohammed Sheikh8Mahmoud Elodemi9Sultan A. Alhumaid10Yasmin N. Ramadan11Noura H. Abd Ellah12Reem Sayad13Division of Microbiology, Immunology and Biotechnology, Department of Natural Products and Alternative Medicine, Faculty of Pharmacy, University of Tabuk, Tabuk 71491, Saudi ArabiaDepartment of Pharmacy Practice, Faculty of Pharmacy, University of Tabuk, Tabuk 71491, Saudi ArabiaDepartment of Internal Medicine (Neurology), Faculty of Medicine, University of Tabuk, Tabuk 71491, Saudi ArabiaDepartment of Family and Community Medicine, Faculty of Medicine, University of Tabuk, Tabuk 71491, Saudi ArabiaDepartment of Family and Community Medicine, Faculty of Medicine, University of Tabuk, Tabuk 71491, Saudi ArabiaDepartment of Internal Medicine, Faculty of Medicine, University of Tabuk, Tabuk 71491, Saudi ArabiaDepartment of Internal Medicine, Faculty of Medicine, University of Tabuk, Tabuk 71491, Saudi ArabiaDepartment of Anatomy, Faculty of Medicine, University of Tabuk, Tabuk 71491, Saudi ArabiaDepartment of Pediatric, Faculty of Medicine, University of Tabuk, Tabuk 71491, Saudi ArabiaDepartment of Pharmacology, Faculty of Medicine, University of Tabuk, Tabuk 71491, Saudi ArabiaDepartment of Family Medicine, King Salman Armed Forces Hospital, Tabuk 71491, Saudi ArabiaDepartment of Microbiology and Immunology, Faculty of Pharmacy, Assiut University, Assiut 71515, EgyptDepartment of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Badr University in Assiut, Naser City 2014101, EgyptDepartment of Histology, Faculty of Medicine, Assiut University, Assiut 71515, Egypt<b>Background/Objectives</b>: Anlotinib is a novel oral antiangiogenic tyrosine kinase inhibitor (TKI) approved as a third-line treatment for advanced non-small-cell lung cancer (NSCLC). However, its efficacy in combination with docetaxel remains incompletely understood. Given the need for effective second-line therapies after platinum-based chemotherapy, this systematic review aims to evaluate the therapeutic potential of anlotinib plus docetaxel in advanced NSCLC. <b>Methods</b>: The PubMed, WOS, Medline, and Scopus databases were screened for published articles up to 12 April 2024. We included RCTs comparing anlotinib plus docetaxel with docetaxel alone in advanced NSCLC after receiving platinum-based chemotherapy, reporting progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR) as outcomes for both groups. <b>Results</b>: Our systematic review included three randomized controlled trials (RCTs) with a total of 151 patients in the anlotinib plus docetaxel group and 132 in the docetaxel-only group. Meta-analysis results demonstrated that the combination therapy significantly prolonged PFS (mean difference (MD) = 2.98, 95% confidence interval (CI), 1.95–4.00; <i>p</i> < 0.00001) and improved ORR (risk ratio (RR) = 3.04, 95% CI = 1.77–5.24; <i>p</i> < 0.00001). Additionally, the DCR was notably higher in the combination group (RR = 1.58, 95% CI = 1.34–1.87; <i>p</i> < 0.00001). <b>Conclusions</b>: Anlotinib plus docetaxel appears to be more effective as a second-line treatment of advanced NSCLC than docetaxel in prolonging PFS and increasing ORR and DCR.https://www.mdpi.com/1424-8247/18/5/652NSCLCnon-small-cell lung canceranlotinibdocetaxelnovel targeted drugnovel multi-targeting tyrosine kinase inhibitor |
| spellingShingle | Helal F. Hetta Saleh F. Alqifari Khaled Alshehri Amirah Alhowiti Saud S. Alharbi Hyder Mirghani Tariq Alrasheed Mohamed E. A. Mostafa Mohammed Sheikh Mahmoud Elodemi Sultan A. Alhumaid Yasmin N. Ramadan Noura H. Abd Ellah Reem Sayad Efficacy of Anlotinib Plus Docetaxel in Advanced NSCLC Previously Treated with Platinum-Based Chemotherapy: A Systematic Review and Meta-Analysis Pharmaceuticals NSCLC non-small-cell lung cancer anlotinib docetaxel novel targeted drug novel multi-targeting tyrosine kinase inhibitor |
| title | Efficacy of Anlotinib Plus Docetaxel in Advanced NSCLC Previously Treated with Platinum-Based Chemotherapy: A Systematic Review and Meta-Analysis |
| title_full | Efficacy of Anlotinib Plus Docetaxel in Advanced NSCLC Previously Treated with Platinum-Based Chemotherapy: A Systematic Review and Meta-Analysis |
| title_fullStr | Efficacy of Anlotinib Plus Docetaxel in Advanced NSCLC Previously Treated with Platinum-Based Chemotherapy: A Systematic Review and Meta-Analysis |
| title_full_unstemmed | Efficacy of Anlotinib Plus Docetaxel in Advanced NSCLC Previously Treated with Platinum-Based Chemotherapy: A Systematic Review and Meta-Analysis |
| title_short | Efficacy of Anlotinib Plus Docetaxel in Advanced NSCLC Previously Treated with Platinum-Based Chemotherapy: A Systematic Review and Meta-Analysis |
| title_sort | efficacy of anlotinib plus docetaxel in advanced nsclc previously treated with platinum based chemotherapy a systematic review and meta analysis |
| topic | NSCLC non-small-cell lung cancer anlotinib docetaxel novel targeted drug novel multi-targeting tyrosine kinase inhibitor |
| url | https://www.mdpi.com/1424-8247/18/5/652 |
| work_keys_str_mv | AT helalfhetta efficacyofanlotinibplusdocetaxelinadvancednsclcpreviouslytreatedwithplatinumbasedchemotherapyasystematicreviewandmetaanalysis AT salehfalqifari efficacyofanlotinibplusdocetaxelinadvancednsclcpreviouslytreatedwithplatinumbasedchemotherapyasystematicreviewandmetaanalysis AT khaledalshehri efficacyofanlotinibplusdocetaxelinadvancednsclcpreviouslytreatedwithplatinumbasedchemotherapyasystematicreviewandmetaanalysis AT amirahalhowiti efficacyofanlotinibplusdocetaxelinadvancednsclcpreviouslytreatedwithplatinumbasedchemotherapyasystematicreviewandmetaanalysis AT saudsalharbi efficacyofanlotinibplusdocetaxelinadvancednsclcpreviouslytreatedwithplatinumbasedchemotherapyasystematicreviewandmetaanalysis AT hydermirghani efficacyofanlotinibplusdocetaxelinadvancednsclcpreviouslytreatedwithplatinumbasedchemotherapyasystematicreviewandmetaanalysis AT tariqalrasheed efficacyofanlotinibplusdocetaxelinadvancednsclcpreviouslytreatedwithplatinumbasedchemotherapyasystematicreviewandmetaanalysis AT mohamedeamostafa efficacyofanlotinibplusdocetaxelinadvancednsclcpreviouslytreatedwithplatinumbasedchemotherapyasystematicreviewandmetaanalysis AT mohammedsheikh efficacyofanlotinibplusdocetaxelinadvancednsclcpreviouslytreatedwithplatinumbasedchemotherapyasystematicreviewandmetaanalysis AT mahmoudelodemi efficacyofanlotinibplusdocetaxelinadvancednsclcpreviouslytreatedwithplatinumbasedchemotherapyasystematicreviewandmetaanalysis AT sultanaalhumaid efficacyofanlotinibplusdocetaxelinadvancednsclcpreviouslytreatedwithplatinumbasedchemotherapyasystematicreviewandmetaanalysis AT yasminnramadan efficacyofanlotinibplusdocetaxelinadvancednsclcpreviouslytreatedwithplatinumbasedchemotherapyasystematicreviewandmetaanalysis AT nourahabdellah efficacyofanlotinibplusdocetaxelinadvancednsclcpreviouslytreatedwithplatinumbasedchemotherapyasystematicreviewandmetaanalysis AT reemsayad efficacyofanlotinibplusdocetaxelinadvancednsclcpreviouslytreatedwithplatinumbasedchemotherapyasystematicreviewandmetaanalysis |